In terms of receiving high-quality therapy, it can be difficult to find the time and funds to go see a therapist. Most doctors will recommend therapy for a wide range of mental health issues, from depression and anxiety to full-on disorders such as OCD and bipolar. If you’re dealing with a mental health concern, you know how crucial it is for you to open up to someone and let them help you through your problems. In order to do this, you need to utilize the benefits of therapy. However, if you don’t have the time or money available to see a therapist, you need a better alternative.
Talkspace was created for people who need access to a therapist without having to spend the fortune that is needed or find the time to keep up with appointments. This is why it is so important that you make the time to download the Talkspace app to your phone or tablet. Talkspace is different from conventional therapy because it allows you to get in touch with a licensed therapist and explain your situation to them through video messaging or text messaging. If you’ve been wary of leaving your home, Talkspace gives you the access to a therapist that you need while keeping you in a safe and secure environment.
You may have heard of Talkspace on television by seeing one of their commercials, but giving them a try can literally transform your life for the better. Now is the time for you to make use of Talkspace and see what it can do for you. It gives you face-to-face access to a licensed therapist who is there to help with all of your problems. Once you begin to go through therapy using the Talkspace app, you’ll never go back to conventional therapy ever again.
When it comes to dealing with rare diseases, Amicus Therapeutics is consistently front and center. The company is currently in the process of developing various technologies to treat aspects of these diseases. Many of these advancements are designed to make life easier for people living with Fabry disease or conditions such as Epidermolysis Bullosa.
What makes Amicus Therapeutics stand out in the industry is their clear dedication to the needs of the people within the rare disease community; everything the company does is to promote better living for both the patients and those that care for them.
Amicus Therapeutics builds its organization and portfolio of clinical programs around science that can mitigate the worst aspects of various rare diseases.
Experts have noted that at this time, the company likely has the broadest portfolio of chaperones for small molecules in the whole industry. The focus of Amicus Therapeutics is primarily developing revolutionary enzyme replacement therapies. Such advancements can help stabilize adverse conditions Fabry disease and the like.
Over time, Amicus has expanded to more research sites including San Diego and acquired competitors and other companies with similar interests and goals. This has allowed Amicus Therapeutics to enhance its available research options and the intellectual properties that were available to advance other research.
In addition to its own capital, Amicus has been awarded several grants and other monies thanks to its successes and cutting-edge research. Various foundations dedicated to neurological research and other fields provided these additional finances knowing that Amicus would be most likely to make a breakthrough.
Amicus Therapeutics doesn’t simply do solid research, they’re also well-known for their dedication to patient advocacy. The company provides initiatives that work to empower patients living with rare diseases. Along with their research, Amicus provides resources and support services to deal with not only the physical aspects of the diseases but the emotional toll they can take as well.
The company takes a comprehensive approach to this by listening to the stories of those affected and their families and incorporating that patient input into their therapies (Crunchbase). Amicus Therapeutics is currently developing several treatment options hoping to provide massive benefits to those dealing with rare and orphan diseases today.
More at http://www.marketwatch.com/investing/stock/fold